Drug intelligence / Profile preview

ALTA-2350

Development stage: Unknown
Lead developer: Sumitovant Biopharma
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

**ALTA-2350** is a novel inhaled formulation of recombinant interleukin-1 receptor antagonist (IL-1Ra), a protein therapeutic designed to inhibit the pro-inflammatory cytokine interleukin-1 (IL-1) by competitively binding to its receptor. Developed for potential use in inflammatory respiratory conditions, it leverages inhalation for targeted lung delivery to block IL-1 mediated inflammation, which drives tissue damage in diseases like acute lung injury or pulmonary fibrosis. Sumitovant Biopharma is advancing it through early nonclinical proof-of-concept studies as of late 2022, highlighting its potential as a localized anti-inflammatory therapy.[9]

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on ALTA-2350.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALTA-2350.

Explore the full profile